Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 93. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening837
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma818
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans790
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China773
Recent advances in targeting protein degradation for tumor immunotherapy741
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ516
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies491
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency479
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects395
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024386
Cancer vaccines: current status and future directions368
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy365
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and336
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases323
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018308
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration298
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p289
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis276
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2274
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression271
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)262
Landscape of biallelic DNMT3A mutant myeloid neoplasms254
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma251
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1241
Ferroptosis: principles and significance in health and disease233
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients224
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors219
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway216
Personalized nanovaccines for treating solid cancer metastases210
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts206
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis202
Recent advances in therapeutic strategies for non-small cell lung cancer201
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation188
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia187
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model182
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?179
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation179
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies179
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis178
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs177
3D chromatin architecture and transcription regulation in cancer177
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy176
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global 176
Small RNA modifications: regulatory molecules and potential applications168
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study164
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer161
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis159
Multiple myeloma risk linked to DNA damage response genes158
Recent advances in targeted strategies for triple-negative breast cancer154
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages151
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response148
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers147
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study147
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry144
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study143
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation141
A single-cell and spatially resolved atlas of human osteosarcomas141
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment140
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis139
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials139
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting135
Target neutrophil heterogeneity and plasticity in cancer134
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia133
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype133
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects128
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts128
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives124
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting124
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer122
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia121
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia120
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia120
The functional and clinical roles of liquid biopsy in patient-derived models117
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting117
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting117
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer117
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies115
Echinomycin as a promising therapeutic agent against KSHV-related malignancies110
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting110
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting109
Worked to the bone: antibody-based conditioning as the future of transplant biology109
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial108
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis106
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives103
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II 102
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination100
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies99
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function98
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives97
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy97
Gastric cancer treatment: recent progress and future perspectives95
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders93
Challenges and new technologies in adoptive cell therapy93
0.163822889328